{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 45,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes a line chart showing concentration over time and a table summarizing safety margin folds at different doses.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/43",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.52,
        "y": 0.47
      },
      "kind": "callout",
      "text": "Based on preclinical exposures (AUC), ELVN-002 had a >10x larger safety margin compared to tucatinib in NHPs (HER2 amp setting)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "899df304-c299-4c2f-800b-a0667d009b74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "ELVN-002 28-day GLP Tox NHP TK",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d40feae-7019-43a9-8c33-0b49deeefc7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "NHP = Non-human primate. NOAEL = No observed adverse event level. Highly Efficacious Exposure equals the total AUC of ELVN-002 at 5 mg/kg in NOD-SCID mouse (836 ng*hr/mL), which yielded robust tumor regression in a HER YVMA xenograft...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cd1c5dd-04ca-47d3-9cd9-57fccfe3568b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "At its 28-day NOAEL, ELVN-002 had a wide safety margin in non-human primates (NHPs) and even wider safety margin in rats; At its approved dose, tucatinib only achieves IC90 all day in ~40% of patients; Due to its larger safety margin, irreversible inhibition and improved PK profile, we believe ELVN-002 has the potential to achieve better target inhibition and improved efficacy compared to tucatinib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b6270df-f7e5-4e3e-be08-c93cd2f60d86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "table",
      "text": "ELVN-002 Safety Margin at NHP NOAEL",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58d116ed-486b-4ef1-baaf-261e62560656",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ELVN-002 Achieved a Wide Safety Margin in Preclinical Species",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20232bb3-74da-4167-aebf-067d021f7daf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}